

# EC declaration of conformity




According to Directive 98/79/EC, Concerning In-Vitro Diagnostic medical device



**Manufacturer:** Xiamen Wiz Biotech CO., LTD.

**Address:** 3-4 Floor, NO. 16 Building, Bio-medical Workshop, 2030 Wengjiao Xi Road, Haicang District, Xiamen City, Fujian Province, 361026, P.R.China



**EU representative:** WellKang Ltd

**Address:** Address: 16 Castle St, Dover, Kent, CT16 1PW, England, UK.

**Product Name:** SARS-CoV-2 Antigen Rapid Test

**Product Type:** 1 Test/kit, 2 Tests/kit, 3Tests/kit, 5 Tests/kit, 10Tests/kit, 20Tests/kit, 25Tests/kit, 30Tests/kit, 40Tests/kit, 50Tests/kit, 100Tests/kit, 200Tests/kit

**Product Classification:** Other IVD device

## We hereby state that:

Those above products with CE marking which are manufactured by our company all comply with EU Medical Device Directives IVDD98/79/EC, and realize their expected uses. All CE files have been certified by the company, consequently their authenticity has been guaranteed.

## Directive we are following:

*In-Vitro Diagnostic medical device:*

*DIRECTIVE 98/79/EC OF EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 27 October1998 on In-Vitro Diagnostic medical device.*

## Standards we are implementing:

EN 13612:2002/AC: 2002    EN ISO 13485:2016    EN ISO 14971:2012  
EN ISO 23640:2015    EN 13641:2002    EN ISO 15223-1:2016  
EN ISO 18113-1:2011    EN ISO 18113-2:2011

Xiamen Wiz Biotech CO., LTD.

XiaMen. China    August 10, 2020

Place    date

  
Signature,    Title



# SGS

Certificate CN19/42110

The management system of

## Xiamen Wiz Biotech Co., Ltd.

3-4 Floor, NO. 16 Building, Bio-medical Workshop, 2030 Wengjiao Xi Road,  
Haicang District, Xiamen City, Fujian Province, 361026, P.R. China

has been assessed and certified as meeting the requirements of



### ISO 13485:2016 EN ISO 13485:2016

For the following activities

**Design and manufacture of in vitro diagnostic medical devices including hormone marker test kit, kidney disease marker test kit, tumor marker test kit, infectious disease marker test kit, gastrointestinal inflammation marker test kit, cardiac marker test kit, immunochromatography analyzer.**

This certificate is valid from 4 September 2019 until 3 September 2022  
and remains valid subject to satisfactory surveillance audits.  
Re certification audit due before 26 July 2022  
Issue 1. Certified since 4 September 2019

Authorised by

A handwritten signature in blue ink, appearing to be 'R' followed by a flourish.



0005

SGS United Kingdom Ltd  
Rosemore Business Park, Ellesmere Port, Cheshire CH65 3EN UK  
t +44 (0)151 350-6666 f +44 (0)151 350-6600 [www.sgs.com](http://www.sgs.com)

HC SGS 13485 2016 0118

Page 1 of 1



This document is issued by the Company subject to its General Conditions of Certification Services accessible at [www.sgs.com/terms\\_and\\_conditions.htm](http://www.sgs.com/terms_and_conditions.htm). Attention is drawn to the limitations of liability, indemnification and jurisdictional issues established therein. The authenticity of this document may be verified at <http://www.sgs.com/en/certified-clients-and-products/certified-client-directory>. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law.





## Internal Market, Industry, Entrepreneurship and SMEs

### **Notification**

**Found : 0**

Body :

**SGS United Kingdom Limited**

Rossmore Business Park  
Ellesmere Port Cheshire CH65 3EN  
Country : United Kingdom

Phone : +44 (0)1934 522917

Fax : +44 (0)1934 522137

Email : [globalmedical@sgs.com](mailto:globalmedical@sgs.com);  
[sgsprodcert@sgs.com](mailto:sgsprodcert@sgs.com) (for 89/686/EEC;  
92/42/EEC)

Website : [www.uk.sgs.com](http://www.uk.sgs.com)

Notified Body number : 0120

**Version(s):** [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#)  
[15](#) [16](#) [17](#) [18](#) [19](#) [20](#) [21](#) **22**

Last approval date : 02/10/2020

### **Legislations**

No data selected





## Statement for the detection of the S glycoprotein mutant strain

Spike glycoprotein exist on the surface of novel coronavirus and easily mutated such as HV69-70 missing, Y144 missing, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H , B-117 ,B-1351 and so on.

The viral nucleocapsid is composed of nucleocapsid protein (N protein for short) and RNA. The N protein is relatively stable, the largest proportion in viral structural proteins and high sensitivity in detection.

Based on the features of N protein, Monoclonal antibody of N protein against novel coronavirus was chosen in the development and design of our product named 'SARS-CoV-2 Antigen Rapid Test' that is intended for the qualitative detection of SARS-CoV-2 Antigen in oropharyngeal swab and nasopharyngeal swab specimens in vitro through the detection of N protein.

That is to say, the current spike glycoprotein mutant strain including UK variant (B-117) and South Africa(B-1351) are not affected by detection.

XIAMEN WIZ BIOTECH CO., LTD

2021.02.17